综述:隐源性组织性肺炎治疗的研究现状

IF 3.3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pulmonary pharmacology & therapeutics Pub Date : 2022-12-01 DOI:10.1016/j.pupt.2022.102175
Christopher Lau , Brannen Liang , Ourfa Hovsepyan , Tom Shreves , Kenneth Wei
{"title":"综述:隐源性组织性肺炎治疗的研究现状","authors":"Christopher Lau ,&nbsp;Brannen Liang ,&nbsp;Ourfa Hovsepyan ,&nbsp;Tom Shreves ,&nbsp;Kenneth Wei","doi":"10.1016/j.pupt.2022.102175","DOIUrl":null,"url":null,"abstract":"<div><p>Cryptogenic organizing pneumonia<span><span><span> is a diffuse interstitial lung disease<span> that starts in the alveolar wall and subsequently expands to the alveolar ducts and respiratory bronchioles. </span></span>Randomized controlled trials<span> are lacking to guide the treatment of cryptogenic </span></span>organizing pneumonia<span>, so treatment decisions and practice guidelines are often based upon observations from case series or expert clinical opinions. The backbone<span> of treatment involves immunosuppression<span> via corticosteroids. In refractory cases, cytotoxic therapy is considered. The evidence that supports the use of these regimens are limited. The goal of this scoping review is to conduct a systematic search of the literature to determine what regimens have been utilized to treat steroid refractory organizing pneumonia and to characterize the evidence supporting their use.</span></span></span></span></p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Scoping review: The state of research on cryptogenic organizing pneumonia therapeutics\",\"authors\":\"Christopher Lau ,&nbsp;Brannen Liang ,&nbsp;Ourfa Hovsepyan ,&nbsp;Tom Shreves ,&nbsp;Kenneth Wei\",\"doi\":\"10.1016/j.pupt.2022.102175\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Cryptogenic organizing pneumonia<span><span><span> is a diffuse interstitial lung disease<span> that starts in the alveolar wall and subsequently expands to the alveolar ducts and respiratory bronchioles. </span></span>Randomized controlled trials<span> are lacking to guide the treatment of cryptogenic </span></span>organizing pneumonia<span>, so treatment decisions and practice guidelines are often based upon observations from case series or expert clinical opinions. The backbone<span> of treatment involves immunosuppression<span> via corticosteroids. In refractory cases, cytotoxic therapy is considered. The evidence that supports the use of these regimens are limited. The goal of this scoping review is to conduct a systematic search of the literature to determine what regimens have been utilized to treat steroid refractory organizing pneumonia and to characterize the evidence supporting their use.</span></span></span></span></p></div>\",\"PeriodicalId\":20799,\"journal\":{\"name\":\"Pulmonary pharmacology & therapeutics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pulmonary pharmacology & therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1094553922000669\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pulmonary pharmacology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1094553922000669","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

摘要

隐源性组织性肺炎是一种弥漫性间质性肺部疾病,发病于肺泡壁,随后扩展到肺泡导管和呼吸性细支气管。缺乏随机对照试验来指导隐源性组织性肺炎的治疗,因此治疗决策和实践指南通常基于病例系列观察或专家临床意见。主要的治疗方法是通过皮质类固醇抑制免疫。在难治性病例中,考虑细胞毒治疗。支持使用这些方案的证据是有限的。本综述的目的是对文献进行系统的检索,以确定治疗类固醇难治性组织性肺炎的方案,并描述支持其使用的证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Scoping review: The state of research on cryptogenic organizing pneumonia therapeutics

Cryptogenic organizing pneumonia is a diffuse interstitial lung disease that starts in the alveolar wall and subsequently expands to the alveolar ducts and respiratory bronchioles. Randomized controlled trials are lacking to guide the treatment of cryptogenic organizing pneumonia, so treatment decisions and practice guidelines are often based upon observations from case series or expert clinical opinions. The backbone of treatment involves immunosuppression via corticosteroids. In refractory cases, cytotoxic therapy is considered. The evidence that supports the use of these regimens are limited. The goal of this scoping review is to conduct a systematic search of the literature to determine what regimens have been utilized to treat steroid refractory organizing pneumonia and to characterize the evidence supporting their use.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
41
审稿时长
42 days
期刊介绍: Pulmonary Pharmacology and Therapeutics (formerly Pulmonary Pharmacology) is concerned with lung pharmacology from molecular to clinical aspects. The subject matter encompasses the major diseases of the lung including asthma, cystic fibrosis, pulmonary circulation, ARDS, carcinoma, bronchitis, emphysema and drug delivery. Laboratory and clinical research on man and animals will be considered including studies related to chemotherapy of cancer, tuberculosis and infection. In addition to original research papers the journal will include review articles and book reviews. Research Areas Include: • All major diseases of the lung • Physiology • Pathology • Drug delivery • Metabolism • Pulmonary Toxicology.
期刊最新文献
Elexacaftor/tezacaftor/ivacaftor, a game-changer in cystic fibrosis: The Portuguese experience Editorial Board Lipid nanoparticles for pulmonary fibrosis: A comprehensive review Ensifentrine approval: A milestone in the treatment of COPD FTO promotes gefitinib-resistance by enhancing PELI3 expression and autophagy in non-small cell lung cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1